Blenrep for Multiple Myeloma Withdrawn From US Market

The manufacturer is pulling the drug from the market at the request of the FDA following disappointing results from a large phase 3 confirmatory trial.
News Alerts

source https://www.medscape.com/viewarticle/984437?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost